Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The genomic features of cancer cells may confer the metastatic ability of lung adenocarcinoma (LUAD) to metastasize to specific organs. We aimed to identify the differences in genomic alterations between patients with primary LUAD with and without metastases and to elucidate the metastatic biology that may help developing biomarker-directed therapies for advanced or metastatic disease.
Methods: A retrospective cohort of 497 patients with LUAD including 388 primary tumors (PR), 53 bone metastases (MT-bone), 30 liver metastases (MT-liver), and 26 brain metastases (MT-brain) was tested for genomic alterations by a next-generation sequencing assay.
Results: The , , , , , , , and genes had a high frequency of mutations, and the mutations were shared by PR and metastases groups. and were the most common mutated genes. In comparison with PR, , , , , and were significantly mutated in MT-brain, and , , , , and were significantly mutated in MT-liver. The frequencies of , , , , and mutations were higher in MT-bone than that in PR. The ERBB, phosphoinositide-3-kinase/protein kinase B (PI3K-AKT), cell cycle, Fibroblast growth factor (FGF), and homologous recombination deficiency signaling pathways were affected in both PR and metastases, and there is higher frequency of mutations in metastases. Moreover, the co-mutations in patients with PR and metastasis were respectively analyzed. In addition, the programmed death ligand 1 (PD-L1) level was obviously related to tumor stage and tumor metastases, and the tumor mutational burden was correlated to clinicopathological features including age, gender, pathological stages, and tumor metastases. , , , , , and were also dramatically correlated to the tumor mutational burden.
Conclusion: Metastases are the most devastating stage of tumors and the main cause of cancer-related deaths. Our results provided a clinically relevant view of the tumor-intrinsic mutational landscape of patients with metastatic LUAD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331737 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.908759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.
Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.
Prognosis of lymph node metastasis confined to lateral pelvic or mesenteric nodes in mid-low rectal cancer: multicentre retrospective cohort study.
BJS Open
September 2025
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Metastases in the lateral pelvic lymph nodes or mesenteric lymph nodes represent distinct categories of mid-low rectal cancer. This study investigated the patterns of mesenteric and lateral pelvic lymph node metastases in mid-low rectal cancer; the survival benefit of postoperative treatment was also analysed in these groups.
Methods: This retrospective multicentre study included consecutive patients with mid-low rectal cancer who underwent total mesorectal excision with lateral pelvic lymph node dissection in three Chinese institutions between 2012 and 2020.
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.
PLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDFTwo Cases of Primary Melanoma of the Uterine Cervix.
Am J Case Rep
September 2025
Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.
View Article and Find Full Text PDFSpindle Cell Spindle Sarcoma Harboring a Novel Gene Fusion.
Int J Surg Pathol
September 2025
Department of Pathology, The Thirteenth People's Hospital of Chongqing, Chongqing, China.
Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal cells. Recent advancements in genomic profiling have identified novel gene fusions in these tumors, offering new insights into their pathogenesis and potential therapeutic targets. Here, we describe a spindle cell sarcoma harboring a novel gene fusion.
View Article and Find Full Text PDF